Fresenius SE & Co. KGaA stock (DE0005785604): Q1 2026 results and valuation metrics in focus
05.06.2026 - 19:42:46 | ad-hoc-news.de
Fresenius SE & Co. KGaA shares were actively traded on Xetra at EUR 34.20 on 06/05/2026, reflecting a modest move as investors continued to digest the company’s latest quarterly figures, according to data from Xetra as of 06/05/2026. The German healthcare group, listed in Germany with the ticker FRE, remains closely watched in its home market as new earnings data and updated analyst views filter into valuation models.
In its Q1 2026 reporting released on 04/30/2026, Fresenius stated that organic revenue increased by 5% year on year while core earnings per share rose 13% compared with Q1 2025, highlighting contributions from efficiency measures and portfolio streamlining, according to the company’s quarterly communication as of 04/30/2026. Management emphasized in the Q1 2026 update that these improvements were achieved across key activities such as hospitals, outpatient services and healthcare products, underscoring the group’s focus on profitable growth.
As of: 05.06.2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: Fresenius
- Sector/industry: Healthcare services and products
- Headquarters/country: Bad Homburg, Germany
- Core markets: Europe, North America and selected emerging markets
- Key revenue drivers: Hospital operations, outpatient care services and medical products
- Home exchange/listing venue: Xetra (FRE)
- Trading currency: EUR
Fresenius SE & Co. KGaA: core business model
Fresenius operates as a diversified healthcare group centered on hospital services, outpatient care and related medical products, aiming to leverage its clinical networks and procurement scale to support earnings.
Valuation metrics and multiples for Fresenius SE & Co. KGaA
Based on the Xetra closing price of approximately EUR 34.20 on 06/05/2026 and the company’s reported improvement in core earnings per share in Q1 2026, investors are paying a valuation that reflects both the recovery in profitability and remaining execution risk, according to Xetra data and the Q1 2026 update as of 04/30/2026. The 13% rise in core EPS for Q1 2026 versus Q1 2025 provides a higher earnings base for commonly used metrics such as the price-earnings ratio, with the market assessing how sustainable these gains will be over the remainder of 2026.
Organic revenue growth of 5% in Q1 2026, as disclosed on 04/30/2026, also feeds into valuation measures like enterprise-value-to-sales and EV/EBITDA, where modest top-line expansion combined with margin improvements can help support multiples if trends continue, according to the company’s Q1 2026 communication as of 04/30/2026. On this basis, the stock’s current pricing on Xetra suggests that market participants are weighing ongoing cost-efficiency benefits against typical regulatory and reimbursement uncertainties in the German and broader European healthcare landscape.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Fresenius SE & Co. KGaA
Following the Q1 2026 figures and the current valuation discussion, investor commentary and retail interest in Fresenius can be followed across major social and video platforms.
Conclusion
With Fresenius SE & Co. KGaA trading around EUR 34 on Xetra and posting 5% organic revenue growth plus a 13% increase in core EPS in Q1 2026, the market is currently valuing the stock on the basis of improving profitability in its German and international healthcare operations. The latest quarterly dynamics and the resulting valuation metrics suggest that investors will closely monitor upcoming quarters to see whether earnings momentum and cost efficiencies can be maintained against a backdrop of regulatory and reimbursement changes.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
